Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79


ArgBP2γ interacts with Akt and p21-activated kinase-1 and promotes cell survival.

Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22845. No abstract available.


Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.

Wang Z, Zhou Q, Kruh GD, Gallo JM.

Drug Metab Dispos. 2011 Nov;39(11):2155-61. doi: 10.1124/dmd.111.041228. Epub 2011 Aug 12.


Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG, Kruh GD.

Cancer Res. 2011 May 15;71(10):3649-57. doi: 10.1158/0008-5472.CAN-10-3623.


Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

Peng XX, Shi Z, Tiwari AK, Damaraju VL, Fu L, Cass CE, Ashby CR Jr, Kruh GD, Chen ZS.

Oncol Lett. 2011 May;2(3):549-556. Epub 2011 Mar 21.


Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors.

Wang F, Zhou F, Kruh GD, Gallo JM.

Neuro Oncol. 2010 Oct;12(10):1043-9. doi: 10.1093/neuonc/noq056. Epub 2010 May 25.


Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.

Guo Y, Köck K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M.

Clin Cancer Res. 2009 Mar 1;15(5):1762-9. doi: 10.1158/1078-0432.CCR-08-0442. Epub 2009 Feb 24.


Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance.

Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD, Chen ZS.

Biochem Pharmacol. 2009 Mar 15;77(6):993-1001. doi: 10.1016/j.bcp.2008.12.005. Epub 2008 Dec 25.


Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B.

Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD.

Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420.


The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Ludueña RF, Kruh GD, Mooberry SL.

Cancer Res. 2008 Nov 1;68(21):8881-8. doi: 10.1158/0008-5472.CAN-08-2037.


ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.

Honorat M, Mesnier A, Vendrell J, Guitton J, Bieche I, Lidereau R, Kruh GD, Dumontet C, Cohen P, Payen L.

Endocr Relat Cancer. 2008 Mar;15(1):125-38. doi: 10.1677/ERC-07-0189.


The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis.

Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3891-6. doi: 10.1073/pnas.0712328105. Epub 2008 Feb 21.


Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.

Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL.

Drug Metab Dispos. 2008 May;36(5):911-5. doi: 10.1124/dmd.107.019273. Epub 2008 Feb 14.


Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine.

Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, Chen ZS.

Leuk Res. 2008 May;32(5):799-809. Epub 2007 Nov 8.


Targeted ablation of Abcc1 or Abcc3 in Abcc6(-/-) mice does not modify the ectopic mineralization process.

Li Q, Jiang Q, Larusso J, Klement JF, Sartorelli AC, Belinsky MG, Kruh GD, Uitto J.

Exp Dermatol. 2007 Oct;16(10):853-9.


Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.

Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM.

Clin Cancer Res. 2007 Jul 15;13(14):4271-9.


Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry.

Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, Gallo JM.

J Pharm Biomed Anal. 2007 Apr 11;43(5):1789-95. Epub 2007 Jan 12.


Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice.

Kruh GD, Belinsky MG, Gallo JM, Lee K.

Cancer Metastasis Rev. 2007 Mar;26(1):5-14. Review.


Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage.

Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, Gallo JM, Kruh GD.

Cancer Res. 2007 Jan 1;67(1):262-8.


ABCC10, ABCC11, and ABCC12.

Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS.

Pflugers Arch. 2007 Feb;453(5):675-84. Epub 2006 Jul 26. Review.


Ins and outs of taxanes.

Kruh GD.

Cancer Biol Ther. 2005 Sep;4(9):1030-2. Epub 2005 Sep 30. No abstract available.


Involvement of palladin and alpha-actinin in targeting of the Abl/Arg kinase adaptor ArgBP2 to the actin cytoskeleton.

Rönty M, Taivainen A, Moza M, Kruh GD, Ehler E, Carpen O.

Exp Cell Res. 2005 Oct 15;310(1):88-98.


Analysis of the in vivo functions of Mrp3.

Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD.

Mol Pharmacol. 2005 Jul;68(1):160-8. Epub 2005 Apr 6.


ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival.

Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ.

J Biol Chem. 2005 Jun 3;280(22):21483-90. Epub 2005 Mar 22. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22845.


Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).

Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD.

Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10.


Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.

Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM.

Cancer Cell. 2004 Aug;6(2):129-37.


Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel.

Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD.

Cancer Res. 2004 Jul 15;64(14):4927-30.


Recruitment of Pyk2 and Cbl to lipid rafts mediates signals important for actin reorganization in growing neurites.

Haglund K, Ivankovic-Dikic I, Shimokawa N, Kruh GD, Dikic I.

J Cell Sci. 2004 May 15;117(Pt 12):2557-68. Epub 2004 May 5.


Lustrous insights into cisplatin accumulation: copper transporters.

Kruh GD.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5807-9. No abstract available.


The MRP family of drug efflux pumps.

Kruh GD, Belinsky MG.

Oncogene. 2003 Oct 20;22(47):7537-52. Review.


Introduction to resistance to anticancer agents.

Kruh GD.

Oncogene. 2003 Oct 20;22(47):7262-4. Review. No abstract available.


Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD.

Cancer Res. 2003 Jul 15;63(14):4048-54.


MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine.

Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD.

J Biol Chem. 2003 Aug 8;278(32):29509-14. Epub 2003 May 22.


Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).

Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD.

Mol Pharmacol. 2003 Feb;63(2):351-8.


Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).

Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD.

Cancer Res. 2002 Nov 1;62(21):6172-7.


Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG.

Iijima Y, Okuda K, Tojo A, Tri NK, Setoyama M, Sakaki Y, Asano S, Tokunaga K, Kruh GD, Sato Y.

Oncogene. 2002 Jun 27;21(28):4374-83.


Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.

Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD.

Cancer Res. 2002 Jun 1;62(11):3144-50.


MRP subfamily transporters and resistance to anticancer agents.

Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG.

J Bioenerg Biomembr. 2001 Dec;33(6):493-501. Review.


Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function.

Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S.

Int J Cancer. 2001 Jul 1;93(1):107-13.


Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily.

Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD.

Cancer Lett. 2001 Jan 26;162(2):181-91.


Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.

Lee K, Klein-Szanto AJ, Kruh GD.

J Natl Cancer Inst. 2000 Dec 6;92(23):1934-40.


Transport of amphipathic anions by human multidrug resistance protein 3.

Zeng H, Liu G, Rea PA, Kruh GD.

Cancer Res. 2000 Sep 1;60(17):4779-84.


Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins.

Belinsky MG, Bain LJ, Balsara BB, Testa JR, Kruh GD.

J Natl Cancer Inst. 1998 Nov 18;90(22):1735-41.


Supplemental Content

Support Center